α-glucosidase x Alpha-amylase x GANC x MGAM

Main research purpose: This study aims to study the pharmacodynamic characteristics of acarbose tablets (specification: 50 mg) developed and produced by Shanghai Modern Pharmaceutical Co., Ltd. when taken orally under fasting conditions, and to compare the pharmacodynamic parameters of the two preparations and evaluate the bioequivalence of the two preparations in humans using acarbose tablets (Baytangping®, specification: 50 mg) certified by Bayer Healthcare Co., Ltd. as the reference preparation. Secondary research purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.

The main research objectives: 1) Using plasma glucose concentration as the pharmacodynamic evaluation index, explore the optimal dose of acarbose tablets produced by Bayer Healthcare Co., Ltd. in healthy Chinese subjects after fasting oral administration to produce pharmacodynamic response, and determine the appropriate dosage for formal bioequivalence trials; 2) Compare the differences in the treatment methods of different pharmacodynamic parameters based on the test results, and explore appropriate equivalence evaluation indicators for formal trials. Secondary research objectives: To study the safety of different doses of acarbose tablets (50 mg, 100 mg and 150 mg) in healthy Chinese subjects.